114798-30-0

Basic information

• Product Name: 2-Butyl-4-chloro-1-[(2'-carboxybiphenyl-4-yl)-methyl]imidazole-5-carboxaldehyde
• Synonyms: 2-Butyl-4-chloro-1-[(2'-carboxybiphenyl-4-yl)-methyl]imidazole-5-carboxaldehyde
• CAS NO: 114798-30-0
• Molecular Weight: 396.873
• Mol File: 114798-30-0.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 2-Butyl-4-chloro-1-[(2'-carboxybiphenyl-4-yl)-methyl]imidazole-5-carboxaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Butyl-4-chloro-1-[(2'-carboxybiphenyl-4-yl)-methyl]imidazole-5-carboxaldehyde(114798-30-0)
• EPA Substance Registry System: 2-Butyl-4-chloro-1-[(2'-carboxybiphenyl-4-yl)-methyl]imidazole-5-carboxaldehyde(114798-30-0)

Safety Data

• Hazardous Substances Data: 114798-30-0(Hazardous Substances Data)

Upstream product

• 114798-27-5 2-butyl-4-chloro-5-hydroxymethyl-1-[(2'carboxybiphenyl-4-yl)methyl]imidazole 
• 57598-33-1 2-(2-methoxyphenyl)-4,4-dimethyl-2-oxazoline 
• 624-31-7 4-tolyl iodide 
• 610-97-9 o-iodo-methyl-benzoic acid 
• 7148-03-0 o-tolylbenzoic acid 
• 114772-34-8 methyl 4'-methylbiphenyl-2-carboxylate 
• 74201-13-1 N-(2-hydroxy-1,1-dimethyl)-2-methoxybenzamide 
• 114772-38-2 Methyl 4'-(bromomethyl)biphenyl-2-carboxylate 
• 84392-32-5 4,4-dimethyl-2-(4'-methyl-biphenyl-2-yl)-4,5-dihydrooxazole 
• 21615-34-9 2-Methoxybenzoyl chloride 
• 579-75-9 2-Methoxybenzoic acid 
• 114772-43-9 2-butyl-4-chloro-5-hydroxymethyl-1-[(2'-methoxycarbonyl-1,1'-biphenyl-4-yl)methyl]-1H-imidazole 

Downstream Products

• 114799-16-5 methyl 2-butyl-1-<(2'-carboxybiphenyl-4-yl)methyl>-4-chloroimidazole-5-carboxylate 
• 114799-17-6 2-butyl-1-<(2'-carboxybiphenyl-4-yl)methyl>-4-chloroimidazole-5-carboxamide 
• 114799-75-6 EXP 8623 

Relevant articles and documents

Use of an angiotensin II receptor antagonist for the preparation of drugs to increase the survival rate of renal transplant patients

The present invention relates to the use, for the preparation of drugs to increase the survival rate of transplant patients, including renal and heart transplant patients, of a therapeutically effective amount of an angiotension II receptor antagonist compound, such as the class of substituted imidazoles represented by formula (I) and in particular by losartan potassium, 2-butyl-4-chloro-[(2′-tetrazol-5-yl)biphenyl-4-il]methyl]-5-(hydroxymethyl)imidazole potassium salt.

Treatment of atherosclerosis with angiotensin II receptor blocking imidazoles

A method of treatment for atherosclerosis and/or reducing cholesterol using an angiotensin II antagonist. This method of treatment can be used in conjunction with the treatment of hypertension. Substituted imidazoles such as STR1 are useful as angiotensin II receptor antagonists for this method of treatment. A method of treatment for atherosclerosis and/or reducing cholesterol using an angiotensin II receptor antagonist in combination with an HMG-Co A reductase inhibitor. A method of treatment for atherosclerosis and/or reducing cholesterol using an angiotensin II receptor antagonist in combination with an HMG-Co A reductase inhibitor and an angiotensin converting enzyme inhibitor. Also within the scope of this invention are pharmaceutical compositions for this method of use.

Treatment of central nervous system disorders with imidazole angiotensin-II receptor antagonists

Substituted imidazoles such as 2-butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydroxymethyl)imidazole and 2-butyl-4-chloro-1-[(2'-carboxybiphenyl-4-yl)-methyl]-5-(hydroxymethyl)imidazole and pharmaceutically acceptable salts thereof are useful for treating central nervous system disorders, such as cognitive and learning disorders, mediated by angiotensin II.